Letter from Egom regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy".
EGOM Clinical and Translational Research Services (ECTRS) Ltd, Halifax, Nova Scotia, Canada.
Emmanuel E
EE
Egom
D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides